Matrixx Confirms Voluntary Recall Of Zicam
Disagrees with FDA's allegations that these products are unsafe and were unlawfully marketed
Matrixx has said that it is in the process of formally notifying retailers, wholesalers and distributors nationwide, of its recall of all Zicam Cold Remedy Nasal Gel and Zicam Cold Remedy Gel Swabs.
Matrixx disagrees with the FDA's allegations that these products are not safe and were unlawfully marketed. However, the company has restated that it is conducting this recall because of its desire to cooperate with the FDA.
The company is also in the process of preparing a submission to the FDA. As previously reported, it will soon ask to meet with the agency to present comprehensive scientific and medical data and analyses, demonstrating that these products are safe.
Related Insight
Suppliers Directory
PharmARC - Analytic Solutions for Efficient Commercialisation of Drugs and Medical Products
PharmARC is a 100% life sciences focused company that provides analytic solutions for efficient commercialization of drugs and medical products. We enable our customers to make informed decisions related to their sales and marketing strategies, and implementation, yielding better ROI.
Suppliers
Biospectra - High Purity Biological Buffers
Biospectra manufactures high purity biological buffers specifically intended for use in biopharm applications.
Suppliers
Pharmassist – Pharmaceutical Contract Research Organisation
Pharmassist is a contract research organisation located in Athens, Greece, providing services in the areas of regulatory affairs, pharmacovigilance, clinical trials, medical economics and biostatistics.
Suppliers
SYSTAG – Laboratory Automation, Scale-up, Thermal Process Safety and Pilot Plant Control From a Single Hand
SYSTAG, System Technik AG is a global provider for lab automation and solutions in the chemical and pharmaceutical industry specialising in integrated automation projects, from development to pilot plant and process control, including thermal process analysing for a safe process design.
Suppliers
Production & Manufacturing
Fine & Speciality Chemicals
Manufacturing
Process & Production
OTC
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Intelligence
Key Factors Influencing Measured Tablet Hardness
Published by Dr Schleuniger Pharmatron
White Papers
Tips & Tricks - GPC/SEC: Copolymer Analysis in GPC/SEC 3 - CompositionaL Analysis by GPC/SEC with Multiple Detection
Published by Polymer Standards Service
White Papers
Analyzing RNA-seq data with Qlucore Omics Explorer
Published by Qlucore
White Papers
Buy the latest industry research online today!
Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Reports Buy online from $3500
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Reports Buy online from $3500
Comments may be moderated for spam, obscenities or defamation.